Antihypertensive efficacy of manidipine and enalapril in hypertensive diabetic patients

Giuseppe Mancia, Stefano Omboni, Enrico Agabiti-Rosei, Rodolfo Casati, Roberto Fogari, Gastone Leonetti, Giuseppe Montemurro, Renato Nami, Achille C. Pessina, Anna Pirrelli, Alberto Zanchetti

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

Recent studies showed that in diabetic hypertensive patients, administration of angiotensin-converting enzyme (ACE)-inhibitors or calcium antagonists can effectively lower blood pressure (BP) and prevent diabetes- related cardiovascular complications with no adverse metabolic effects. We sought to assess the antihypertensive and metabolic effects of the new dihydropyridine calcium antagonist manidipine (M) in patients with diabetes mellitus and essential hypertension as compared with the ACE inhibitor enalapril (E). After 3 weeks of placebo, 101 (62 men; age range, 34-72 years) hypertensives with type II diabetes mellitus were randomized to M 10-20 mg or E 10-20 mg, od, for 24 weeks. At the end of the placebo period and the active-treatment phase, BP was measured with a mercury sphygmomanometer (office, O) and over the 24 h by ambulatory (A) monitoring. ABP recordings were analyzed to obtain 24-h, day (6 a.m. to midnight), and night (midnight to 6 a.m.) average systolic (S) and diastolic (D) BP and heart rate (HR) values. Homogeneity of the antihypertensive effect over the 24 h was assessed by the smoothness index [SI; i.e:, the ratio between the average of the 24 hourly BP changes after treatment and the corresponding standard deviation (the higher the SI, the more uniform is the BP control by treatment over the 24 h]. The O SBP and DBP were significantly (p <0.01) and similarly reduced by M (16 ± 10 and 13 ± 6 mm Hg, n = 49) and E (15 ± 10 and 13 ± 6 mm Hg, n = 45). The percentage of patients whose O DBP was reduced ≤85 mm Hg (i:e., the value indicated to be the optimal DBP goal in diabetic hypertensives) was similar for M (37%) and E (40%). The reduction of 24-h BP also was similar between M (n = 38) and E (n = 38) for both drugs (systolic, 6 ± 11 and 8 ± 10 mm Hg; diastolic, 5 ± 8 and 5 ±7 ; NS, M vs. E). The antihypertensive effect was distributed in a similar homogeneous fashion throughout the dosing interval, as shown by the similar SI values (M, 0.6 ± 1.2 for SBP and 0.6 ± 0.9 for DBP; E, 0.6 ± 0.8 for SBP and 0.5 ± 0.7 for DBP; NS, M vs. E). O and A HR were unchanged by either treatment. Markers of glucose and lipid metabolism and renal function were not significantly modified by treatment both with M and with E. In the diabetic hypertensives, M was as effective and metabolically neutral as the ACE-inhibitor E.

Original languageEnglish
Pages (from-to)926-931
Number of pages6
JournalJournal of Cardiovascular Pharmacology
Volume35
Issue number6
DOIs
Publication statusPublished - 2000

Fingerprint

manidipine
Enalapril
Antihypertensive Agents
Blood Pressure
Angiotensin-Converting Enzyme Inhibitors
Heart Rate
Placebos
Sphygmomanometers
Calcium
Therapeutics
Ambulatory Monitoring
Diabetes Complications
Mercury
Lipid Metabolism
Type 2 Diabetes Mellitus
Diabetes Mellitus

Keywords

  • Ambulatory blood pressure monitoring
  • Diabetes mellitus
  • Enalapril
  • Essential hypertension
  • Manidipine
  • Office blood pressure

ASJC Scopus subject areas

  • Pharmacology
  • Cardiology and Cardiovascular Medicine

Cite this

Mancia, G., Omboni, S., Agabiti-Rosei, E., Casati, R., Fogari, R., Leonetti, G., ... Zanchetti, A. (2000). Antihypertensive efficacy of manidipine and enalapril in hypertensive diabetic patients. Journal of Cardiovascular Pharmacology, 35(6), 926-931. https://doi.org/10.1097/00005344-200006000-00015

Antihypertensive efficacy of manidipine and enalapril in hypertensive diabetic patients. / Mancia, Giuseppe; Omboni, Stefano; Agabiti-Rosei, Enrico; Casati, Rodolfo; Fogari, Roberto; Leonetti, Gastone; Montemurro, Giuseppe; Nami, Renato; Pessina, Achille C.; Pirrelli, Anna; Zanchetti, Alberto.

In: Journal of Cardiovascular Pharmacology, Vol. 35, No. 6, 2000, p. 926-931.

Research output: Contribution to journalArticle

Mancia, G, Omboni, S, Agabiti-Rosei, E, Casati, R, Fogari, R, Leonetti, G, Montemurro, G, Nami, R, Pessina, AC, Pirrelli, A & Zanchetti, A 2000, 'Antihypertensive efficacy of manidipine and enalapril in hypertensive diabetic patients', Journal of Cardiovascular Pharmacology, vol. 35, no. 6, pp. 926-931. https://doi.org/10.1097/00005344-200006000-00015
Mancia, Giuseppe ; Omboni, Stefano ; Agabiti-Rosei, Enrico ; Casati, Rodolfo ; Fogari, Roberto ; Leonetti, Gastone ; Montemurro, Giuseppe ; Nami, Renato ; Pessina, Achille C. ; Pirrelli, Anna ; Zanchetti, Alberto. / Antihypertensive efficacy of manidipine and enalapril in hypertensive diabetic patients. In: Journal of Cardiovascular Pharmacology. 2000 ; Vol. 35, No. 6. pp. 926-931.
@article{365717d845864aa7b42909f37fe672bf,
title = "Antihypertensive efficacy of manidipine and enalapril in hypertensive diabetic patients",
abstract = "Recent studies showed that in diabetic hypertensive patients, administration of angiotensin-converting enzyme (ACE)-inhibitors or calcium antagonists can effectively lower blood pressure (BP) and prevent diabetes- related cardiovascular complications with no adverse metabolic effects. We sought to assess the antihypertensive and metabolic effects of the new dihydropyridine calcium antagonist manidipine (M) in patients with diabetes mellitus and essential hypertension as compared with the ACE inhibitor enalapril (E). After 3 weeks of placebo, 101 (62 men; age range, 34-72 years) hypertensives with type II diabetes mellitus were randomized to M 10-20 mg or E 10-20 mg, od, for 24 weeks. At the end of the placebo period and the active-treatment phase, BP was measured with a mercury sphygmomanometer (office, O) and over the 24 h by ambulatory (A) monitoring. ABP recordings were analyzed to obtain 24-h, day (6 a.m. to midnight), and night (midnight to 6 a.m.) average systolic (S) and diastolic (D) BP and heart rate (HR) values. Homogeneity of the antihypertensive effect over the 24 h was assessed by the smoothness index [SI; i.e:, the ratio between the average of the 24 hourly BP changes after treatment and the corresponding standard deviation (the higher the SI, the more uniform is the BP control by treatment over the 24 h]. The O SBP and DBP were significantly (p <0.01) and similarly reduced by M (16 ± 10 and 13 ± 6 mm Hg, n = 49) and E (15 ± 10 and 13 ± 6 mm Hg, n = 45). The percentage of patients whose O DBP was reduced ≤85 mm Hg (i:e., the value indicated to be the optimal DBP goal in diabetic hypertensives) was similar for M (37{\%}) and E (40{\%}). The reduction of 24-h BP also was similar between M (n = 38) and E (n = 38) for both drugs (systolic, 6 ± 11 and 8 ± 10 mm Hg; diastolic, 5 ± 8 and 5 ±7 ; NS, M vs. E). The antihypertensive effect was distributed in a similar homogeneous fashion throughout the dosing interval, as shown by the similar SI values (M, 0.6 ± 1.2 for SBP and 0.6 ± 0.9 for DBP; E, 0.6 ± 0.8 for SBP and 0.5 ± 0.7 for DBP; NS, M vs. E). O and A HR were unchanged by either treatment. Markers of glucose and lipid metabolism and renal function were not significantly modified by treatment both with M and with E. In the diabetic hypertensives, M was as effective and metabolically neutral as the ACE-inhibitor E.",
keywords = "Ambulatory blood pressure monitoring, Diabetes mellitus, Enalapril, Essential hypertension, Manidipine, Office blood pressure",
author = "Giuseppe Mancia and Stefano Omboni and Enrico Agabiti-Rosei and Rodolfo Casati and Roberto Fogari and Gastone Leonetti and Giuseppe Montemurro and Renato Nami and Pessina, {Achille C.} and Anna Pirrelli and Alberto Zanchetti",
year = "2000",
doi = "10.1097/00005344-200006000-00015",
language = "English",
volume = "35",
pages = "926--931",
journal = "Journal of Cardiovascular Pharmacology",
issn = "0160-2446",
publisher = "Lippincott Williams and Wilkins",
number = "6",

}

TY - JOUR

T1 - Antihypertensive efficacy of manidipine and enalapril in hypertensive diabetic patients

AU - Mancia, Giuseppe

AU - Omboni, Stefano

AU - Agabiti-Rosei, Enrico

AU - Casati, Rodolfo

AU - Fogari, Roberto

AU - Leonetti, Gastone

AU - Montemurro, Giuseppe

AU - Nami, Renato

AU - Pessina, Achille C.

AU - Pirrelli, Anna

AU - Zanchetti, Alberto

PY - 2000

Y1 - 2000

N2 - Recent studies showed that in diabetic hypertensive patients, administration of angiotensin-converting enzyme (ACE)-inhibitors or calcium antagonists can effectively lower blood pressure (BP) and prevent diabetes- related cardiovascular complications with no adverse metabolic effects. We sought to assess the antihypertensive and metabolic effects of the new dihydropyridine calcium antagonist manidipine (M) in patients with diabetes mellitus and essential hypertension as compared with the ACE inhibitor enalapril (E). After 3 weeks of placebo, 101 (62 men; age range, 34-72 years) hypertensives with type II diabetes mellitus were randomized to M 10-20 mg or E 10-20 mg, od, for 24 weeks. At the end of the placebo period and the active-treatment phase, BP was measured with a mercury sphygmomanometer (office, O) and over the 24 h by ambulatory (A) monitoring. ABP recordings were analyzed to obtain 24-h, day (6 a.m. to midnight), and night (midnight to 6 a.m.) average systolic (S) and diastolic (D) BP and heart rate (HR) values. Homogeneity of the antihypertensive effect over the 24 h was assessed by the smoothness index [SI; i.e:, the ratio between the average of the 24 hourly BP changes after treatment and the corresponding standard deviation (the higher the SI, the more uniform is the BP control by treatment over the 24 h]. The O SBP and DBP were significantly (p <0.01) and similarly reduced by M (16 ± 10 and 13 ± 6 mm Hg, n = 49) and E (15 ± 10 and 13 ± 6 mm Hg, n = 45). The percentage of patients whose O DBP was reduced ≤85 mm Hg (i:e., the value indicated to be the optimal DBP goal in diabetic hypertensives) was similar for M (37%) and E (40%). The reduction of 24-h BP also was similar between M (n = 38) and E (n = 38) for both drugs (systolic, 6 ± 11 and 8 ± 10 mm Hg; diastolic, 5 ± 8 and 5 ±7 ; NS, M vs. E). The antihypertensive effect was distributed in a similar homogeneous fashion throughout the dosing interval, as shown by the similar SI values (M, 0.6 ± 1.2 for SBP and 0.6 ± 0.9 for DBP; E, 0.6 ± 0.8 for SBP and 0.5 ± 0.7 for DBP; NS, M vs. E). O and A HR were unchanged by either treatment. Markers of glucose and lipid metabolism and renal function were not significantly modified by treatment both with M and with E. In the diabetic hypertensives, M was as effective and metabolically neutral as the ACE-inhibitor E.

AB - Recent studies showed that in diabetic hypertensive patients, administration of angiotensin-converting enzyme (ACE)-inhibitors or calcium antagonists can effectively lower blood pressure (BP) and prevent diabetes- related cardiovascular complications with no adverse metabolic effects. We sought to assess the antihypertensive and metabolic effects of the new dihydropyridine calcium antagonist manidipine (M) in patients with diabetes mellitus and essential hypertension as compared with the ACE inhibitor enalapril (E). After 3 weeks of placebo, 101 (62 men; age range, 34-72 years) hypertensives with type II diabetes mellitus were randomized to M 10-20 mg or E 10-20 mg, od, for 24 weeks. At the end of the placebo period and the active-treatment phase, BP was measured with a mercury sphygmomanometer (office, O) and over the 24 h by ambulatory (A) monitoring. ABP recordings were analyzed to obtain 24-h, day (6 a.m. to midnight), and night (midnight to 6 a.m.) average systolic (S) and diastolic (D) BP and heart rate (HR) values. Homogeneity of the antihypertensive effect over the 24 h was assessed by the smoothness index [SI; i.e:, the ratio between the average of the 24 hourly BP changes after treatment and the corresponding standard deviation (the higher the SI, the more uniform is the BP control by treatment over the 24 h]. The O SBP and DBP were significantly (p <0.01) and similarly reduced by M (16 ± 10 and 13 ± 6 mm Hg, n = 49) and E (15 ± 10 and 13 ± 6 mm Hg, n = 45). The percentage of patients whose O DBP was reduced ≤85 mm Hg (i:e., the value indicated to be the optimal DBP goal in diabetic hypertensives) was similar for M (37%) and E (40%). The reduction of 24-h BP also was similar between M (n = 38) and E (n = 38) for both drugs (systolic, 6 ± 11 and 8 ± 10 mm Hg; diastolic, 5 ± 8 and 5 ±7 ; NS, M vs. E). The antihypertensive effect was distributed in a similar homogeneous fashion throughout the dosing interval, as shown by the similar SI values (M, 0.6 ± 1.2 for SBP and 0.6 ± 0.9 for DBP; E, 0.6 ± 0.8 for SBP and 0.5 ± 0.7 for DBP; NS, M vs. E). O and A HR were unchanged by either treatment. Markers of glucose and lipid metabolism and renal function were not significantly modified by treatment both with M and with E. In the diabetic hypertensives, M was as effective and metabolically neutral as the ACE-inhibitor E.

KW - Ambulatory blood pressure monitoring

KW - Diabetes mellitus

KW - Enalapril

KW - Essential hypertension

KW - Manidipine

KW - Office blood pressure

UR - http://www.scopus.com/inward/record.url?scp=12944254453&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=12944254453&partnerID=8YFLogxK

U2 - 10.1097/00005344-200006000-00015

DO - 10.1097/00005344-200006000-00015

M3 - Article

C2 - 10836728

AN - SCOPUS:12944254453

VL - 35

SP - 926

EP - 931

JO - Journal of Cardiovascular Pharmacology

JF - Journal of Cardiovascular Pharmacology

SN - 0160-2446

IS - 6

ER -